Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 519.8 DKK -1.07%
Market Cap: 37.1B DKK

Zealand Pharma A/S
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Zealand Pharma A/S
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Zealand Pharma A/S
CSE:ZEAL
Operating Income
kr7.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Operating Income
kr1.3B
CAGR 3-Years
28%
CAGR 5-Years
3%
CAGR 10-Years
35%
Ascendis Pharma A/S
NASDAQ:ASND
Operating Income
-€145.8m
CAGR 3-Years
35%
CAGR 5-Years
13%
CAGR 10-Years
-15%
B
Bavarian Nordic A/S
CSE:BAVA
Operating Income
kr2.5B
CAGR 3-Years
N/A
CAGR 5-Years
29%
CAGR 10-Years
33%
Bioporto A/S
CSE:BIOPOR
Operating Income
-kr93.4m
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
-21%
Saniona AB
STO:SANION
Operating Income
kr608.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zealand Pharma A/S
Glance View

Market Cap
36.5B DKK
Industry
Biotechnology

Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.

ZEAL Intrinsic Value
392.64 DKK
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Zealand Pharma A/S's Operating Income?
Operating Income
7.3B DKK

Based on the financial report for Sep 30, 2025, Zealand Pharma A/S's Operating Income amounts to 7.3B DKK.

Back to Top